GDC-0980 + bevacizumab + paclitaxel

This is a **combination regimen** of three agents: - **GDC-0980 (apitolisib)**, an oral small molecule dual inhibitor of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), which targets the PI3K/AKT/mTOR pathway implicated in cancer cell proliferation and survival[3][5][6]. - **Bevacizumab**, a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis essential for tumor growth. - **Paclitaxel**, a microtubule-stabilizing antineoplastic agent that promotes microtubule assembly and inhibits their disassembly, leading to cell cycle arrest and apoptosis. This combination is under investigation in oncology, particularly for the treatment of advanced or recurrent solid tumors such as endometrial carcinoma, due to the complementary mechanisms of targeting tumor cell proliferation (GDC-0980), tumor vascularization (bevacizumab), and cytotoxic action (paclitaxel)[1][3][5][6].